IS8362A - Hámörkuð tjáning HPV 45 L1 í gersveppi - Google Patents

Hámörkuð tjáning HPV 45 L1 í gersveppi

Info

Publication number
IS8362A
IS8362A IS8362A IS8362A IS8362A IS 8362 A IS8362 A IS 8362A IS 8362 A IS8362 A IS 8362A IS 8362 A IS8362 A IS 8362A IS 8362 A IS8362 A IS 8362A
Authority
IS
Iceland
Prior art keywords
hpv
yeast
maximum expression
expression
maximum
Prior art date
Application number
IS8362A
Other languages
English (en)
Other versions
IS2694B (is
Inventor
T. Bryan Janine
K. Brownlow Michelle
D. Schultz Loren
U. Jansen Kathrin
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS8362A publication Critical patent/IS8362A/is
Publication of IS2694B publication Critical patent/IS2694B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IS8362A 2003-09-29 2006-03-20 Hámörkuð tjáning HPV 45 L1 í gersveppi IS2694B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (2)

Publication Number Publication Date
IS8362A true IS8362A (is) 2006-03-20
IS2694B IS2694B (is) 2010-11-15

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8362A IS2694B (is) 2003-09-29 2006-03-20 Hámörkuð tjáning HPV 45 L1 í gersveppi

Country Status (33)

Country Link
US (2) US7250170B2 (is)
EP (1) EP1673106B1 (is)
JP (4) JP5451960B2 (is)
KR (1) KR101165278B1 (is)
CN (1) CN1859923B (is)
AR (2) AR045804A1 (is)
AT (1) ATE435029T1 (is)
AU (1) AU2004277934B2 (is)
BE (1) BE2015C072I2 (is)
BR (1) BRPI0414845B8 (is)
CA (1) CA2539168C (is)
CY (2) CY1110525T1 (is)
DE (1) DE602004021828D1 (is)
DK (1) DK1673106T3 (is)
ES (1) ES2327530T3 (is)
FR (1) FR15C0083I2 (is)
HU (1) HUS1500063I1 (is)
IL (1) IL174458A (is)
IS (1) IS2694B (is)
LT (2) LTPA2015049I1 (is)
LU (1) LU92902I2 (is)
MX (1) MXPA06003457A (is)
MY (1) MY140664A (is)
NL (1) NL300776I2 (is)
NO (3) NO339932B1 (is)
NZ (1) NZ545834A (is)
PL (1) PL1673106T3 (is)
PT (1) PT1673106E (is)
RU (1) RU2360001C2 (is)
SI (1) SI1673106T1 (is)
TW (1) TWI350853B (is)
WO (1) WO2005032586A1 (is)
ZA (1) ZA200601961B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CA2560487C (en) * 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
MX2007013472A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
EP2059262B1 (en) * 2006-08-28 2013-08-21 Sungkyunkwan University Foundation for Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
MX344751B (es) * 2007-11-23 2017-01-05 Shanghai Zerun Biotechnology Co Ltd Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos.
KR101181907B1 (ko) 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
EP2722389B1 (en) * 2011-06-15 2018-03-07 Hong Jin Kim Method for enhancing the production yield of human papillomavirus l1 protein
AU2012272788B2 (en) 2011-06-24 2016-10-20 Merck Sharp & Dohme Llc HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280793B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
CA2927434C (en) 2013-10-16 2022-07-19 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
AU2015313756A1 (en) * 2014-09-11 2017-03-09 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
TW202140069A (zh) 2020-02-14 2021-11-01 美商默沙東藥廠 Hpv疫苗
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
US20230118665A1 (en) 2021-08-19 2023-04-20 Merck Sharp & Dohme Llc Novel thermostable lipid nanoparticle and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK147696A3 (en) * 1994-05-16 1997-08-06 Merck & Co Inc Isolated and purified protein of papillomavirus, a capside, a viral particle, pharmaceutical composition comprising its, a method of making them and their use
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
CA2280195A1 (en) 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO1998054339A1 (en) * 1997-05-27 1998-12-03 Hanil Synthetic Fiber Co., Ltd. PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE)
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
DE69933875T2 (de) * 1998-08-14 2007-05-31 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
ATE290013T1 (de) * 1998-12-23 2005-03-15 Merck & Co Inc Neutralsierungs-assay, das humane papillomavirus- ähnliche partikel verwendet
WO2001014416A2 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
DK1301614T3 (da) 2000-07-21 2007-04-02 Glaxo Group Ltd Codon-optimerede papillomavirus-sekvenser
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2381964T3 (es) 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura

Also Published As

Publication number Publication date
US20060240040A1 (en) 2006-10-26
CN1859923B (zh) 2012-09-05
EP1673106A1 (en) 2006-06-28
SI1673106T1 (sl) 2009-12-31
KR20070029628A (ko) 2007-03-14
AU2004277934B2 (en) 2009-09-17
BRPI0414845B8 (pt) 2021-06-15
KR101165278B1 (ko) 2012-07-23
ES2327530T3 (es) 2009-10-30
AR077396A2 (es) 2011-08-24
HUS1500063I1 (hu) 2016-02-29
CN1859923A (zh) 2006-11-08
FR15C0083I2 (fr) 2016-11-25
CY2015050I2 (el) 2016-06-22
ZA200601961B (en) 2007-05-30
NZ545834A (en) 2009-02-28
LTPA2015049I1 (lt) 2016-01-11
TWI350853B (en) 2011-10-21
WO2005032586A1 (en) 2005-04-14
LTC1673106I2 (lt) 2017-05-10
JP2014221052A (ja) 2014-11-27
NL300776I1 (is) 2015-12-29
DK1673106T3 (da) 2009-11-09
NL300776I2 (is) 2015-12-29
AR045804A1 (es) 2005-11-16
NO339932B1 (no) 2017-02-20
JP2016136947A (ja) 2016-08-04
CA2539168A1 (en) 2005-04-14
CA2539168C (en) 2011-05-31
CY2015050I1 (el) 2016-06-22
BRPI0414845B1 (pt) 2020-10-13
US20080138361A1 (en) 2008-06-12
AU2004277934A1 (en) 2005-04-14
MXPA06003457A (es) 2006-06-05
NO2022051I1 (no) 2022-11-30
NO20061876L (no) 2006-04-28
BE2015C072I2 (is) 2023-12-14
NO2017012I1 (no) 2017-04-05
BRPI0414845A (pt) 2006-11-21
JP5451960B2 (ja) 2014-03-26
IS2694B (is) 2010-11-15
JP2007507207A (ja) 2007-03-29
DE602004021828D1 (de) 2009-08-13
ATE435029T1 (de) 2009-07-15
JP2011152137A (ja) 2011-08-11
US7250170B2 (en) 2007-07-31
MY140664A (en) 2010-01-15
EP1673106B1 (en) 2009-07-01
PT1673106E (pt) 2009-09-22
RU2006114701A (ru) 2007-11-10
IL174458A0 (en) 2006-08-01
US7482015B2 (en) 2009-01-27
IL174458A (en) 2014-06-30
TW200521233A (en) 2005-07-01
CY1110525T1 (el) 2015-04-29
LU92902I2 (fr) 2016-03-08
PL1673106T3 (pl) 2009-12-31
RU2360001C2 (ru) 2009-06-27
FR15C0083I1 (fr) 2016-08-01

Similar Documents

Publication Publication Date Title
IS2694B (is) Hámörkuð tjáning HPV 45 L1 í gersveppi
IS8425A (is) Hámörkuð tjáning af HPV 58 L1 í gersveppi
HUS1500062I1 (hu) HPV 52 L1 optimalizált expresszáltatása élesztõben
DE60317699D1 (de) Fermentationsverfahren und -zusammensetzungen
ATE488224T1 (de) Aerosol-formulierungen von diisobutyryl apomorphine
EP1914233B8 (en) Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors
DE602004022088D1 (de) Zellkultivierungskolben
ITMI20030514A1 (it) Metodo e dispositivo per determinare la frequenza di
ATE453321T1 (de) Flüssige hefe-zusammensetzungen
ITMO20020037A1 (it) Mezzi decoratori, metodo per produrre mezzi decoratori e kit di mezzidecoratori
UA6746S (uk) Кобза чотириструнна
ES1054141Y (es) Mueble archivador de portaplanos y mapas
AU2003244824A1 (en) Improvements in and relating to pumps
ITMC20030128A1 (it) Conversione in positivo della spinta negativa tramite
ITMI20030484V0 (it) Struttura di supporto di oggetti in genere
UA9216S (uk) Комплект патерлиць і хреста
FI6322U1 (fi) Suoramarkkinointikirjekuiori sekä sen aihio